Latest News

Deals this week: Affigen, Albany Molecular Research, Bristol-Myers Squibb

In a series A venture financing round, US-based biotechnology company Affigen has raised $17m to be utilised for advancing the company’s lead programmes in a number of haematological...

Deals this week: Affigen, Albany Molecular Research, Bristol-Myers Squibb

Abivax to screen new antiviral molecules to develop therapeutic candidates against dengue fever

French biotechnology company Abivax has discovered new antiviral molecules and is screening them to develop therapeutic candidates against dengue fever....

Abivax to screen new antiviral molecules to develop therapeutic candidates against dengue fever

M&As this week: Zhejiang Conba Pharmaceutical, Biolennia Laboratories

Zhejiang Conba Pharmaceutical has sold 57.3% stake in a pharmaceutical company for ¥345.1m...

M&As this week: Zhejiang Conba Pharmaceutical, Biolennia Laboratories

US FDA awards orphan drug designation to Minoryx’s MIN-102 compound

US FDA awards orphan drug designation to Minoryx’s MIN-102 compound

Valeant and EyeGate sign licensing agreement

Valeant Pharmaceuticals has signed an agreement for global commercial and manufacturing rights to US-based EyeGate Pharmaceuticals’ new technology and EGP-437 combination product candidate to...

Valeant and EyeGate sign licensing agreement

Northwell Health and GE Ventures collaborate to research bioelectronic medicine

Northwell Health and GE Ventures collaborate to research bioelectronic medicine

US FDA accepts regulatory submission for Pfizer’s inotuzumab ozogamicin

US-based pharmaceutical company Pfizer’s biologics licence application (BLA) for inotuzumab ozogamicin has been accepted for filing and granted priority review by the US Food and...

US FDA accepts regulatory submission for Pfizer’s inotuzumab ozogamicin

Neovacs and BioSense partner to develop and commercialise IFNa Kinoid in China

French-based Neovacs has signed a commercial licence option agreement with BioSense Global for the development and commercial rights of IFNα Kinoid vaccine to treat lupus and dermatomyositis in...

Neovacs and BioSense partner to develop and commercialise IFNa Kinoid in China

AstraZeneca and TerSera sign agreement to commercialise Zoladex in US and Canada

UK-based AstraZeneca has entered an agreement to sell the commercial rights for Zoladex (goserelin acetate implant) in the US and Canadian markets to pharmaceutical company TerSera...

AstraZeneca and TerSera sign agreement to commercialise Zoladex in US and Canada

US FDA grants fast-track designation to Cell Medica's CMD-003

The US Food and Drug Administration (FDA) has granted fast-track designation to UK-based cellular immunotherapy firm Cell Medica's oncology product CMD-003...

US FDA grants fast-track designation to Cell Medica's CMD-003

Mereo BioPharma’s BPS-804 drug accepted for participation in EMA’s adaptive pathways programme

UK-based biopharmaceutical company Mereo BioPharma has announced that its BPS-804 drug has been accepted to participate in the European Medicines Agency’s (EMA) adaptive pathways programme....

Mereo BioPharma’s BPS-804 drug accepted for participation in EMA’s adaptive pathways programme

Sobi renews Ammonul distribution agreement with Valeant Pharmaceuticals

Sobi renews Ammonul distribution agreement with Valeant Pharmaceuticals

Recipharm acquires Kemwell’s pharmaceutical businesses in India for $118.5m

Sweden's Recipharm has completed the previously announced acquisition of Kemwell’s pharmaceutical businesses in Bengaluru, India, in a deal valued at Skr1.05bn...

Recipharm acquires Kemwell’s pharmaceutical businesses in India for $118.5m

Amygdala Neurosciences to acquire GS-6637 from Gilead Sciences

US-based Amygdala Neurosciences has signed an agreement to acquire GS-6637, a ALDH2 inhibitor from Gilead...

Amygdala Neurosciences to acquire GS-6637 from Gilead Sciences

US researchers find vitamin B3 prevents glaucoma

US researchers find vitamin B3 prevents glaucoma

Novartis and NHS Ayrshire & Arran launch new eye care facility in Scotland

Novartis Pharmaceuticals UK and NHS Ayrshire & Arran have announced the launch of a new facility designed specifically for people suffering from some of the most common forms of avoidable sight loss....

Novartis and NHS Ayrshire & Arran launch new eye care facility in Scotland

Is digital disruption of heart disease markets on the horizon?

Is digital disruption of heart disease markets on the horizon?

Cutting costs but not quality: heart failure hospitalisations

Cutting costs but not quality: heart failure hospitalisations

Japan’s Takeda acquires US cancer drug manufacturer ARIAD for $5.2bn

Japan’s Takeda acquires US cancer drug manufacturer ARIAD for $5.2bn

M&As this week: Stada Arzneimittel, NexImmune

German pharmaceutical company Stada Arzneimittel is intended to be fully acquired by either Cinven Partners and Advent International Corporation, which have both submitted...

M&As this week: Stada Arzneimittel, NexImmune

Vedanta, Stanford and Leiden universities partner to study food allergies in children

US-based Vedanta Biosciences has collaborated with Stanford University School of Medicine and Leiden University Medical Center to study food allergies in children and patients with C...

Vedanta, Stanford and Leiden universities partner to study food allergies in children
cachename:Newscachekey:rd-1665407042_1857678299_rd-488908060_1460672566_rd1460672566_371857150_ap1460672566_1857678299_946450448